NCT05384379 - Efficacy and Safety Evaluation of BZ371B in ARDS Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 23, 2022

Primary Completion Date

March 3, 2023

Study Completion Date

March 3, 2023

Conditions

ARDSARDS, HumanPulmonary Disease

Interventions

DRUG

Inhaled BZ371B

Intubated patients suffering from ARDS will receive BZ371B in a dose of 12 mg. This will be divided into 2 nebulizations, each with 10 ml. The first nebulization is at a dose of 3 mg and the second at a dose of 9 mg.

Trial Locations (1)

05403-900

InCor USP, São Paulo